Home/Investors/Vertex Pharmaceuticals

Vertex Pharmaceuticals

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$4.9B

Focus Areas

9

Top Stage

Approved

Investment Focus

Hemoglobinopathies Oncology Regenerative Medicine Cardiovascular Disease Central Nervous System (CNS) Diseases Genetic Diseases Neuromuscular Disorders Metabolic Diseases Genetic Disorders

Portfolio Companies

Company	Stage	Valuation	Focus
CRISPR Therapeutics	Approved	$4.4B	Hemoglobinopathies, Oncology
Entrada Therapeutics	Phase 1/2	$433.0M	Neuromuscular Disorders, Metabolic Diseases

Frequent Co-Investors

Public shareholders1 shared Atlas Venture1 shared Bayer AG1 shared MPM Capital1 shared 5AM Ventures1 shared Roche Venture Fund1 shared